Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018

References

• Frey S , Patouraux S , Debs T , Gugenheim J , Anty R , Iannelli A . Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy. Surg Obes Relat Dis . 2020;16(12):2050–2057. doi:10.1016/j.soard.2020.07.009 32788075
   PubMed Web of Science ®Google Scholar
• Lonardo A , Mantovani A , Lugari S , Targher G . NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci . 2019;20(11):11. doi:10.3390/ijms20112841
   Web of Science ®Google Scholar
• Eslam M , Newsome PN , Sarin SK , et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol . 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039 32278004
   PubMed Web of Science ®Google Scholar
• Eslam M , Sanyal AJ , George J ; International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology . 2020;158(7):1999–2014 e1991. doi:10.1053/j.gastro.2019.11.312 32044314
   PubMed Web of Science ®Google Scholar
• Byrne CD , Targher G . NAFLD as a driver of chronic kidney disease. J Hepatol . 2020;72(4):785–801. doi:10.1016/j.jhep.2020.01.013 32059982
   PubMed Web of Science ®Google Scholar
• Zelnick LR , Weiss NS , Kestenbaum BR , et al. Diabetes and CKD in the United States population, 2009–2014. Clin J Am Soc Nephrol . 2017;12(12):1984–1990. doi:10.2215/CJN.03700417 29054846
   PubMed Web of Science ®Google Scholar
• Bowe B , Xie Y , Li T , et al. Changes in the US burden of chronic kidney disease from 2002 to 2016: an analysis of the Global Burden of Disease Study. JAMA Netw Open . 2018;1(7):e184412. doi:10.1001/jamanetworkopen.2018.4412 30646390
   PubMed Web of Science ®Google Scholar
• Targher G , Bertolini L , Rodella S , Lippi G , Zoppini G , Chonchol M . Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol . 2010;5(12):2166–2171. doi:10.2215/CJN.05050610 20724519
   PubMed Web of Science ®Google Scholar
• Choe AR , Ryu D-R , Kim HY , et al. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol . 2020;21(1):50. doi:10.1186/s12882-020-01718-8 32066395
   PubMed Web of Science ®Google Scholar
• Lin M , Liu C , Liu Y , et al. Fetuin-B links nonalcoholic fatty liver disease to chronic kidney disease in obese Chinese adults: a Cross-Sectional Study. Ann Nutr Metab . 2019;74(4):287–295. doi:10.1159/000499843 30965331
   PubMed Web of Science ®Google Scholar
• Lee YJ , Wang CP , Hung WC , et al. Common and unique factors and the bidirectional relationship between chronic kidney disease and nonalcoholic fatty liver in type 2 diabetes patients. Diabetes Metab Syndr Obes . 2020;13:1203–1214. doi:10.2147/DMSO.S237700 32368113
   PubMed Web of Science ®Google Scholar
• Sirota JC , McFann K , Targher G , Chonchol M , Jalal DI . Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988–1994. Am J Nephrol . 2012;36(5):466–471. doi:10.1159/000343885 23128368
   PubMed Web of Science ®Google Scholar
• Akahane T , Akahane M , Namisaki T , et al. Association between non-alcoholic fatty liver disease and chronic kidney disease: a Cross-Sectional Study. J Clin Med . 2020;9(6):1635. doi:10.3390/jcm9061635
   Web of Science ®Google Scholar
• Musso G , Gambino R , Tabibian JH , et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med . 2014;11(7):e1001680. doi:10.1371/journal.pmed.1001680 25050550
   PubMed Web of Science ®Google Scholar
• Mantovani A , Zaza G , Byrne CD , et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism . 2018;79:64–76. doi:10.1016/j.metabol.2017.11.003 29137912
   PubMed Web of Science ®Google Scholar
• Lin S , Huang J , Wang M , et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int . 2020;40(9):2082–2089. doi:10.1111/liv.14548 32478487
   PubMed Web of Science ®Google Scholar
• Sun DQ , Jin Y , Wang TY , et al. MAFLD and risk of CKD. Metabolism . 2021;115:154433. doi:10.1016/j.metabol.2020.154433 33212070
   PubMed Web of Science ®Google Scholar
• Levey AS , Stevens LA , Schmid CH , et al. A new equation to estimate glomerular filtration rate. Ann Intern Med . 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006 19414839
   PubMed Web of Science ®Google Scholar
• Yilmaz Y , Byrne CD , Musso G . A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol . 2020;1–8. doi:10.1080/17474124.2021.1860019
   Web of Science ®Google Scholar
• Gheith O , Farouk N , Nampoory N , Halim MA , Al-Otaibi T . Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol . 2016;5(1):49–56.28197499
   PubMedGoogle Scholar
• Fioretto P . Diabetic kidney disease: the onset of a new era? J Nephrol . 2020;33(5):899–900. doi:10.1007/s40620-020-00849-3 32902772
   PubMed Web of Science ®Google Scholar
• Russo GT , De Cosmo S , Viazzi F , et al. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr . 2018;18(1):38. doi:10.1186/s12877-018-0732-4 29394888
   PubMed Web of Science ®Google Scholar
• Sharaf El Din UAA , Salem MM , Abdulazim DO . Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res . 2017;8(5):537–548. doi:10.1016/j.jare.2016.11.004 28748119
   PubMed Web of Science ®Google Scholar
• De Becker B , Borghi C , Burnier M , van de Borne P . Uric acid and hypertension: a focused review and practical recommendations. J Hypertens . 2019;37(5):878–883. doi:10.1097/HJH.0000000000001980 30620339
   PubMed Web of Science ®Google Scholar
• Oh TR , Choi HS , Kim CS , et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep . 2019;9(1):6681. doi:10.1038/s41598-019-43241-3 31040373
   PubMed Web of Science ®Google Scholar
• Bonino B , Leoncini G , Russo E , Pontremoli R , Viazzi F . Uric acid in CKD: has the jury come to the verdict? J Nephrol . 2020;33(4):715–724. doi:10.1007/s40620-020-00702-7 31933161
   PubMed Web of Science ®Google Scholar
• Srivastava A , Kaze AD , McMullan CJ , Isakova T , Waikar SS . Uric Acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis . 2018;71(3):362–370.29132945
   PubMed Web of Science ®Google Scholar
• Lora CM , Ricardo AC , Chen J , et al. Prevalence, awareness, and treatment of hypertension in hispanics/latinos with CKD in the Hispanic Community Health Study/Study of Latinos. Kidney Med . 2020;2(3):332–340. doi:10.1016/j.xkme.2020.02.005 32734253
   PubMedGoogle Scholar
• Babu M , Drawz P . Masked hypertension in CKD: increased prevalence and risk for cardiovascular and renal events. Curr Cardiol Rep . 2019;21(7):58. doi:10.1007/s11886-019-1154-4 31111326
   PubMed Web of Science ®Google Scholar
• Gabriele MM , Koch Nogueira PC . Management of hypertension in CAKUT: protective factor for CKD. Front Pediatr . 2019;7:222. doi:10.3389/fped.2019.00222 31214554
   PubMed Web of Science ®Google Scholar
• Initiative CfDCaP-CKD. Chronic Kidney Disease in the United States, 2019 ; 2019.
   Google Scholar
• Pan LL , Zhang HJ , Huang ZF , et al. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: a cross-sectional study. Metabolism . 2015;64(9):1077–1085. doi:10.1016/j.metabol.2015.06.003 26144271
   PubMed Web of Science ®Google Scholar
• Chalasani N , Younossi Z , Lavine JE , et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology . 2018;67(1):328–357.28714183
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol . 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004 27062661
   PubMed Web of Science ®Google Scholar
• Eslam M , Sarin SK , Wong VW , et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int . 2020;14(6):889–919.33006093
   PubMed Web of Science ®Google Scholar
• Eren F , Kaya E , Yilmaz Y . Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol . 2020. doi:10.1097/MEG.0000000000001946
   Web of Science ®Google Scholar
• McPherson S , Hardy T , Dufour J-F , et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol . 2017;112(5):740–751. doi:10.1038/ajg.2016.453 27725647
   PubMed Web of Science ®Google Scholar